XML 25 R6.htm IDEA: XBRL DOCUMENT v3.25.4
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($)
$ in Thousands
Total
Total stockholders’ equity attributable to Barinthus Biotherapeutics plc stockholders
Ordinary Shares
Deferred Shares
Additional Paid-in-Capital
Accumulated Deficit
Accumulated Other Comprehensive Loss
Noncontrolling Interest
Beginning balance (in shares) at Dec. 31, 2023     38,643,540 63,443        
Beginning balance at Dec. 31, 2023 $ 186,995 $ 186,784 $ 1 $ 86 $ 386,602 $ (176,590) $ (23,315) $ 211
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Share based compensation 4,709 4,709     4,709      
Issue of ordinary shares, net of issuance costs (in shares)     1,591,123          
Issue of ordinary shares, net of issuance costs 2,163 2,163 $ 0 [1]   2,163      
Foreign currency translation adjustments (2,549) (2,553)         (2,553) 4
Net loss (61,183) (61,074)       (61,074)   (109)
Ending balance (in shares) at Dec. 31, 2024     40,234,663 63,443        
Ending balance at Dec. 31, 2024 130,135 130,029 $ 1 $ 86 393,474 (237,664) (25,868) 106
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Share based compensation 468 468     468      
Issue of ordinary shares, net of issuance costs (in shares)     614,230          
Issue of ordinary shares, net of issuance costs 2 2 $ 0 [1]   2      
Foreign currency translation adjustments 10,145 10,137         10,137 8
Net loss (66,458) (66,428)       (66,428)   (30)
Ending balance (in shares) at Dec. 31, 2025     40,848,893 63,443        
Ending balance at Dec. 31, 2025 $ 74,292 $ 74,208 $ 1 $ 86 $ 393,944 $ (304,092) $ (15,731) $ 84
[1] Indicates amount less than one thousand